CPH 82 [Reumacon®] is a purified semi-synthetic lignan glycoside derivative of the medicinal herbPodophyllum emodiwhich inhibits microtubules. It has been jointly developed by the Swedish company Conpharm and the Swiss company Analytecon SA. It has potential for the treatment of rheumatoid arthritis.The Swedish company Meda is licencing the drug and has taken over responsibility from Conpharm for development and documentation. Meda has obtained exclusive marketing rights for Reumacon®worldwide, except in China and some other Asian countries. Meda plans to form partnerships with other companies in the marketing of Reumacon®.